CN105326900A - Application of lavender active extract in preparing drug for treating senile dementia - Google Patents
Application of lavender active extract in preparing drug for treating senile dementia Download PDFInfo
- Publication number
- CN105326900A CN105326900A CN201510528733.7A CN201510528733A CN105326900A CN 105326900 A CN105326900 A CN 105326900A CN 201510528733 A CN201510528733 A CN 201510528733A CN 105326900 A CN105326900 A CN 105326900A
- Authority
- CN
- China
- Prior art keywords
- lavandula angustifolia
- extract
- activity extract
- activity
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of lavender active extract, in particular to application of lavender active extract in preparing drug for treating senile dementia. The lavender active extract is lavender active extract A or lavender active extract B or lavender active extract C or lavender active extract D or lavender active extract E. The lavender active extract can restore reaction capability of senile dementia model group zebra fish to different degrees. The lavender active extract D has treatment effect on senile dementia model group zebra fish and can improve dyskinesia of the senile dementia model group zebra fish and remarkably restore the reaction capability of the senile dementia model group zebra fish; when concentration is 50ug/mL, treatment effect, on dyskinesia of the senile dementia model group zebra fish, of the lavender active extract D is equivalent to that of DPZ, and improvement on the reaction capability is better than that of DPZ.
Description
Technical field
the present invention relates to lavandula angustifolia activity extract technical field, is the application 1 of a kind of lavandula angustifolia activity extract in preparation treatment medicine for senile dementia.
Background technology
china has been a society progressively entering aging, and the sickness rate of Alzheimer increases year by year, and research shows, in 65 years old to 69 years old crowd, the prevalence of AD patient rises to 56.1/1000ths by 2.8/1000ths.More unfortunately, nearest research confirms that the sickness rate ascendant trend of AD speeds, and a Hispanic research shows, more than in 90 years old age group, the sickness rate of AD reaches more than 20%.And another population cohort study of Bulgaria shows, in over-65s population, the patient being diagnosed as AD reaches 7.2%, wherein based on the AD sickness rate of modal cognitive disorder infringement for 3.1%.Therefore, AD progressively just becoming entire society and medical circle must faced by sternness and urgent problem, be more and more subject to the attention of the People's Government and medical profession.Alzheimer is a kind of is main clinical manifestation with learning memory disorder, cognitive dysfunction, aphasis, the Progressive symmetric erythrokeratodermia neurodegenerative disease being major pathologic features with senile plaque, neurofibrillary tangle and neuron loss.The pathogenesis of AD is very complicated, its pathogenesis is not yet clearly set forth, but putative theory mainly contains oxidative stress hypothesis, amyloid cascade hypothesis, the low hypothesis of cholinergic and apoptosis hypothesis etc., the existing medicine for clinical treatment is based on acetylcholinesteraseinhibitors inhibitors.Content and the ability of learning and memory of central neurotransmitter and receptor have close relationship, especially the content of acetylcholine.Research shows, the acetylcholine of brain release number determine the power of memory ability, the acetylcholine of high-load can impel brain memory more details.Ability of learning and memory declines and Cholinergic disorder has direct relation, and the acetyl choline content suffered from amnemonic brain brain obviously reduces.Scopolamine is the inhibitor acting on Acetylcholine Muscarinic Receptor, is combined and reduces the effect of acetylcholine, cause learning memory disorder by blockage of acetylcholine with m receptor.According to " Uigurs medicine will " and folk tradition medicine book, lavandula angustifolia has as the conventional use of medical material: 1. control muscle flesh and arthralgia ， epilepsy, depression, and abnormal lymphatic temperament and black gallbladder matter increase, and get appropriate lavandula angustifolia, decoct soup, for oral administration.(" white palace ").2. control head abnormal savda, weakly to have a guilty conscience, thinking weakens, all kinds of poisoning, gets appropriate lavandula angustifolia, decocts soup and takes orally.(" visit according to medicine book ").3. control and tremble, traumatic dizziness, dizzy, cerebral concussion, intelligence declines and gets appropriate lavandula angustifolia, decocts soup, with proper honey water with taking.4. Zhi epilepsy, depression, psychosis, forgetful, murmur to oneself, muscle muscle relaxation or muscle flesh jerks and takes out, extremity tremble, go into a coma, be on tenterhooks and get appropriate lavandula angustifolia, decoct soup and take orally.Recent domestic mainly concentrates on exploitation and the composition Study of lavenderessential oil to the research of lavandula angustifolia, but the concern given for other extract of lavandula angustifolia is little, and the residue of extraction is abandoned as rubbish substantially.Along with some researcheres turn one's attention to the lavandula angustifolia activity research except quintessence oil; in recent years; find that lavender liquid extract also has antioxidant activity and the diastole effect to vascular ring, ethanol extract can be protected chemical liver injury and suppress the growth of cancer cells of liver lung.But up to now, there are no the relevant report of lavandula angustifolia activity extract control senile dementia.
Summary of the invention
the invention provides the application of a kind of lavandula angustifolia activity extract in preparation treatment medicine for senile dementia, overcome the deficiency of above-mentioned prior art, its can effectively solve lavandula angustifolia activity extract preparation control medicine for senile dementia in application also do not have relevant report problem.
technical scheme of the present invention is realized by following measures: the application of a kind of lavandula angustifolia activity extract in preparation treatment medicine for senile dementia.
here is the further optimization and/or improvements to foregoing invention technical scheme:
above-mentioned lavandula angustifolia activity extract is lavandula angustifolia activity extract A or lavandula angustifolia activity extract B or lavandula angustifolia activity extract C or lavandula angustifolia activity extract D or lavandula angustifolia activity extract E.
above-mentioned lavandula angustifolia activity extract A obtains as follows: the first step, lavender flower grain is pulverized and obtains broken lavender flower grain, the ethanol water of broken lavender flower grain 5 doubly to 25 times quality is added in broken lavender flower grain, reflux, extract, 2 times to 3 times at temperature is 45 DEG C to 100 DEG C, each reflux, extract, 0.5h to 1h, lavandula angustifolia extracting solution is obtained after filtrate being merged after reflux, extract, lavandula angustifolia extracting solution is through concentrating and after drying, obtaining the lavandula angustifolia crude extract that percent mass water content is less than or equal to 15%; Second step, the deionized water mix homogeneously adding lavandula angustifolia crude extract 5 doubly to 10 times quality in lavandula angustifolia crude extract obtains suspension, the petroleum ether of suspension 1 doubly to 3 times volume is added and mix homogeneously in suspension, leave standstill 15min to 30min to extract, extract 2 times to 3 times, after extraction, obtain the first raffinate phase, merge each extraction phase and obtain the first extraction phase, first extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract A that percent mass water content is less than or equal to 15%.
above-mentioned lavandula angustifolia activity extract B obtains as follows: in the first raffinate phase, add the chloroform of the first raffinate phase 1 doubly to 3 times volume and mix homogeneously, leave standstill 15min to 30min to extract, extract 2 times to 3 times, the second raffinate phase is obtained after extraction, merge each extraction phase and obtain the second extraction phase, second extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract B that percent mass water content is less than or equal to 15%.
above-mentioned lavandula angustifolia activity extract C obtains as follows: in the second raffinate phase, add the ethyl acetate of the second raffinate phase 1 doubly to 3 times volume and mix homogeneously, leave standstill 15min to 60min to extract, extract 2 times to 3 times, the 3rd raffinate phase is obtained after extraction, merge each extraction phase and obtain the 3rd extraction phase, 3rd extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract C that percent mass water content is less than or equal to 15%.
above-mentioned lavandula angustifolia activity extract D obtains as follows: in the 3rd raffinate phase, add the n-butyl alcohol of the 3rd raffinate phase 1 doubly to 3 times volume and mix homogeneously, leave standstill 15min to 60min to extract, extract 2 times to 3 times, the 4th raffinate phase is obtained after extraction, merge each extraction phase and obtain the 4th extraction phase, 4th extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract D that percent mass water content is less than or equal to 15%.
above-mentioned lavandula angustifolia activity extract E obtains as follows: the 4th raffinate phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract E that percent mass water content is less than or equal to 15%.
in the above-mentioned first step, ethanol water to be percent by volume be 10% to 90% ethanol water.
lavandula angustifolia activity extract A of the present invention, lavandula angustifolia activity extract B, lavandula angustifolia activity extract C, lavandula angustifolia activity extract D and lavandula angustifolia activity extract E all can the responds of recovery Senlie dementia model group Brachydanio rerio in various degree; Lavandula angustifolia activity extract D of the present invention has therapeutical effect to Senlie dementia model group Brachydanio rerio, can not only improve the dyskinesia of Senlie dementia model group Brachydanio rerio, and significantly can recover Senlie dementia model group Brachydanio rerio respond; When concentration is 50 μ g/mL, lavandula angustifolia activity extract D of the present invention is suitable with DPZ to the therapeutical effect of the dyskinesia of Senlie dementia model group Brachydanio rerio, and is better than DPZ to the improvement of respond.
Accompanying drawing explanation
accompanying drawing 1 is the process flow diagram of lavandula angustifolia activity extract in the present invention.
Detailed description of the invention
the present invention by the restriction of following embodiment, can not determine concrete embodiment according to technical scheme of the present invention and practical situation.
embodiment 1, the application of this lavandula angustifolia activity extract in preparation treatment medicine for senile dementia.
embodiment 2, as the optimization of above-described embodiment, lavandula angustifolia activity extract is lavandula angustifolia activity extract A or lavandula angustifolia activity extract B or lavandula angustifolia activity extract C or lavandula angustifolia activity extract D or lavandula angustifolia activity extract E.
embodiment 3, as shown in Figure 1, as the optimization of above-described embodiment, lavandula angustifolia activity extract A obtains as follows: the first step, lavender flower grain is pulverized and obtains broken lavender flower grain, the ethanol water of broken lavender flower grain 5 doubly to 25 times quality is added in broken lavender flower grain, reflux, extract, 2 times to 3 times at temperature is 45 DEG C to 100 DEG C, each reflux, extract, 0.5h to 1h, lavandula angustifolia extracting solution is obtained after filtrate being merged after reflux, extract, lavandula angustifolia extracting solution is after concentrated and drying, obtain the lavandula angustifolia crude extract that percent mass water content is less than or equal to 15%, second step, the deionized water mix homogeneously adding lavandula angustifolia crude extract 5 doubly to 10 times quality in lavandula angustifolia crude extract obtains suspension, the petroleum ether of suspension 1 doubly to 3 times volume is added and mix homogeneously in suspension, leave standstill 15min to 30min to extract, extract 2 times to 3 times, after extraction, obtain the first raffinate phase, merge each extraction phase and obtain the first extraction phase, first extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract A that percent mass water content is less than or equal to 15%.
embodiment 4, as shown in Figure 1, as the optimization of above-described embodiment, lavandula angustifolia activity extract B obtains as follows: in the first raffinate phase, add the chloroform of the first raffinate phase 1 doubly to 3 times volume and mix homogeneously, leaves standstill 15min to 30min and extracts, extract 2 times to 3 times, the second raffinate phase is obtained after extraction, merge each extraction phase and obtain the second extraction phase, the second extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract B that percent mass water content is less than or equal to 15%.
embodiment 5, as shown in Figure 1, as the optimization of above-described embodiment, lavandula angustifolia activity extract C obtains as follows: in the second raffinate phase, add the ethyl acetate of the second raffinate phase 1 doubly to 3 times volume and mix homogeneously, leave standstill 15min to 60min to extract, extract 2 times to 3 times, the 3rd raffinate phase is obtained after extraction, merge each extraction phase and obtain the 3rd extraction phase, 3rd extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract C that percent mass water content is less than or equal to 15%.
embodiment 6, as shown in Figure 1, as the optimization of above-described embodiment, lavandula angustifolia activity extract D obtains as follows: in the 3rd raffinate phase, add the n-butyl alcohol of the 3rd raffinate phase 1 doubly to 3 times volume and mix homogeneously, leaves standstill 15min to 60min and extracts, extract 2 times to 3 times, the 4th raffinate phase is obtained after extraction, merge each extraction phase and obtain the 4th extraction phase, the 4th extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract D that percent mass water content is less than or equal to 15%.
embodiment 7, as shown in Figure 1, as the optimization of above-described embodiment, lavandula angustifolia activity extract E obtains as follows: the 4th raffinate phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract E that percent mass water content is less than or equal to 15%.
embodiment 8, as the optimization of above-described embodiment, in the first step, ethanol water to be percent by volume be 10% to 90% ethanol water.
the preliminary study of the lavandula angustifolia activity extract that the above embodiment of the present invention obtains
1.1 experiment material
1.1.1 the preparation of different solvents component
the lavandula angustifolia activity extract A that the above embodiment of the present invention obtains, lavandula angustifolia activity extract B, lavandula angustifolia activity extract C, lavandula angustifolia activity extract D and lavandula angustifolia activity extract E by percent by volume be respectively 0.1% DSMO aqueous dissolution to concentration be the storing solution of 50mg/ml, after dissolving, label is A, B, C, D and E successively, in faint yellow or brown ,-20 DEG C of preservations.
experimental apparatus and reagent
anatomic microscope (SMZ645, Nikon company); 6 orifice plates, 48 orifice plates (NestBiotech); Behavior analysis instrument (V3, ViewPointLifeSciences company); Donepezil (120011-70-3; TRC; Canada).
laboratory animal
the Brachydanio rerio juvenile fish of experiment is naturally hatched form by zebra fingerling fish produces embryo.Fish culture water water quality: add 200mg Instant Ocean in every 1L reverse osmosis water, electrical conductivity is that 480 μ S/cm to 510 μ S/cm, pH are 6.9 to 7.2, hardness is 53.7mg/L to 71.6mg/LCaCO
3
.After having tested, with the tricaine methanesulfonic acid of 0.25mg/ml, anesthesia is carried out to the Brachydanio rerio of each stage of development and put to death.The operating procedure that anesthesia is put to death meets the code requirement that American Veterinary association (AVMA) puts to death Animal Anesthesia.
experimental design
this research experiment group is set to: blank group, solvent control group, Senlie dementia model group, positive controls (donepezil, and treatment group DPZ), the DSMO aqueous solution that treatment group can be 0.1% by percent by volume is as required diluted to different concentration, treatment group and lavandula angustifolia activity extract A of the present invention, lavandula angustifolia activity extract B of the present invention, lavandula angustifolia activity extract C of the present invention, lavandula angustifolia activity extract D of the present invention and lavandula angustifolia activity extract E of the present invention, the primary dcreening operation concentration for the treatment of group is 50 μ g/mL, if occur dead or lopsided, then reduce concentration to test.The Brachydanio rerio of aluminum chloride process is Senlie dementia model group (Model); The Brachydanio rerio of aluminum chloride and DPZ co-treatment is positive controls; The Brachydanio rerio of aluminum chloride and lavandula angustifolia activity extract co-treatment of the present invention is treatment group; The Brachydanio rerio of the DMSO process of 0.1% is solvent control group, and each experimental group all processes 30 tail Brachydanio rerio.Utilize the movement locus of Brachydanio rerio in behavior analysis instrument record 60min, changed by light dark period, dark 10min, illumination 10min, 60min is divided into three light dark periods, then carries out statistical analysis to the movement velocity (dyskinesia) of Brachydanio rerio, light and shade period velocity change (respond).
quality control standard
this research is tested in strict accordance with following 4 quality control standards: 1. in all experimental grouies, Brachydanio rerio all can not occur death or deformity; 2. Senlie dementia model group and solvent control group compare and have significant difference (p<0.05); 3. blank group and solvent control group no difference of science of statistics (p>0.05); 4. positive controls (donepezil, DPZ) compares with Senlie dementia model group and has significant difference (p<0.05).
result and discussion
1.4.1 quality control
this result of study meets quality control standard: 1. in whole experimentation, all experimental grouies all do not occur that Brachydanio rerio is dead or lopsided; 2. Senlie dementia model group and solvent control group compare and have significant difference (p<0.05); 3. all experiment empty matched groups no difference of science of statistics (p>0.05) compared with solvent control group; 4. positive controls (donepezil, DPZ) compares with Senlie dementia model group and has significant difference (p<0.05).
lavandula angustifolia activity extract concentration of the present invention is determined
grope experimental result according to concentration in early stage, finally determine that the primary dcreening operation concentration of lavandula angustifolia activity extract treatment group of the present invention is 50 μ g/mL, detectable concentration is lower than without visible illeffects levels dosages (NOAEL).
lavandula angustifolia activity extract of the present invention is to the restitution of Senlie dementia model group Brachydanio rerio dyskinesia
lavandula angustifolia activity extract of the present invention on the impact of Senlie dementia model group Brachydanio rerio movement velocity (evaluation dyskinesia) (+: speed is recovered;-: invalid) be shown in Table 1, as can be seen from Table 1, Senlie dementia model group Brachydanio rerio movement velocity significantly declines, and more all has statistical significance (p<0.05) with solvent control group; Positive controls (donepezil, DPZ) Brachydanio rerio movement velocity is significantly gone up, and compares have statistical significance (p<0.05) with Senlie dementia model group.In lavandula angustifolia activity extract of the present invention, lavandula angustifolia activity extract A, lavandula angustifolia activity extract B and lavandula angustifolia activity extract D significantly recover the movement velocity of Senlie dementia model group Brachydanio rerio, significantly improve (p<0.05 or p<0.01) compared with Senlie dementia model group; Lavandula angustifolia activity extract C of the present invention and lavandula angustifolia activity extract E of the present invention significantly can not recover Senlie dementia model group Brachydanio rerio movement velocity (p>0.05).
lavandula angustifolia activity extract of the present invention is on the impact of Senlie dementia model group Brachydanio rerio respond
lavandula angustifolia activity extract of the present invention on the impact of Senlie dementia model group Brachydanio rerio speed difference (+: respond is recovered,-: invalid) be shown in Table 2, as can be seen from Table 2, Senlie dementia model group Brachydanio rerio respond declines (light and shade period velocity difference significantly declines), compares have significant difference (p<0.05) with solvent control group, positive controls (donepezil, DPZ) Brachydanio rerio respond is significantly recovered (light and shade period velocity difference is significantly gone up), compares have statistical significance (p<0.05) with Senlie dementia model group, lavandula angustifolia activity extract A of the present invention, lavandula angustifolia activity extract B, lavandula angustifolia activity extract C, lavandula angustifolia activity extract D and lavandula angustifolia activity extract E all can the respond (rise of light and shade period velocity difference) of recovery Senlie dementia model group Brachydanio rerio in various degree, compared with Senlie dementia model group, lavandula angustifolia activity extract B of the present invention, lavandula angustifolia activity extract C of the present invention and lavandula angustifolia activity extract D significant difference of the present invention are significantly or extremely significantly (p<0.05 or p<0.01), lavandula angustifolia activity extract A of the present invention and lavandula angustifolia activity extract E of the present invention does not have significance to improve (p>0.05) to Senlie dementia model group Brachydanio rerio light and shade period velocity difference.
conclusion
lavandula angustifolia activity extract of the present invention the results are shown in Table shown in 3 to senile dementia drug effect primary dcreening operation, as can be seen from Table 3, lavandula angustifolia activity extract A of the present invention, lavandula angustifolia activity extract B of the present invention, lavandula angustifolia activity extract C of the present invention, in lavandula angustifolia activity extract D of the present invention and lavandula angustifolia activity extract E of the present invention, what motor capacity significance recovered has lavandula angustifolia activity extract A of the present invention, lavandula angustifolia activity extract B of the present invention and lavandula angustifolia activity extract D of the present invention, what respond was significantly recovered has component lavandula angustifolia activity extract of the present invention B, lavandula angustifolia activity extract C of the present invention and lavandula angustifolia activity extract D of the present invention, what two indices all significantly recovered has lavandula angustifolia activity extract B of the present invention and lavandula angustifolia activity extract D of the present invention, illustrate that lavandula angustifolia activity extract B of the present invention and lavandula angustifolia activity extract D of the present invention has therapeutical effect to senile dementia.
the further investigation of the lavandula angustifolia activity extract D activity that the above embodiment of the present invention obtains
2.1 materials and methods
2.1.1 experiment material
lavandula angustifolia activity extract D 100%DMSO of the present invention is mixed with the storing solution that concentration is 150mM, in faint yellow, and-20 DEG C of preservations.
experimental apparatus and reagent
anatomic microscope (SMZ645, Nikon company); 6 orifice plates, 48 orifice plates (NestBiotech); Behavior analysis instrument (V3, ViewPointLifeSciences company); Donepezil (120011-70-3; TRC; Canada).
laboratory animal
zebrafish embryo is produced voluntarily by the special biology of ring; The breeding of Brachydanio rerio is carried out in the mode of natural paired cross; Each copulation prepares 4 to 5 pairs of Adult Zebrafishs, and on average often pair can be produced 200 to 300 embryos.At after fertilization 6 hours (i.e. 6hpf) and 24hpf, embryo is cleared up (removing dead embryo), and select suitable embryo (Kimmeletal.1995) according to the stage of development of embryo.Embryo's (fish culture water water quality: add 200mg Instant Ocean in every 1L reverse osmosis water, electrical conductivity is that 480 μ S/cm to 510 μ S/cm, pH are 6.9 to 7.2, hardness is 53.7mg/L to 71.6mg/LCaCO is hatched with fish culture water under 28 DEG C of conditions
3
).Because embryo can obtain nutrient substance from the yolk sac of self, so (9dpf) does not need feeding in after fertilization 9 days.After having tested, with tricaine methanesulfonic acid, over-exposure process is carried out to the Brachydanio rerio of each stage of development, thus Brachydanio rerio anesthesia is put to death.The operating procedure that anesthesia is put to death meets the code requirement that American Veterinary association (AVMA) puts to death Animal Anesthesia.
experimental technique
this research experiment group is set to: the treatment group of three concentration (25 μ g/mL, 50 μ g/mL and 150 μ g/mL) of blank group, solvent control group, Senlie dementia model group, positive controls (donepezil, DPZ), lavandula angustifolia activity extract D of the present invention.The Brachydanio rerio of aluminum chloride process is Senlie dementia model group; The Brachydanio rerio of aluminum chloride and DPZ co-treatment is positive controls; The Brachydanio rerio of aluminum chloride and lavandula angustifolia activity extract D co-treatment of the present invention is treatment group; The Brachydanio rerio of the DMSO process of 0.1% is solvent control group, and each experimental group all processes 30 tail Brachydanio rerio.Utilize the movement locus of Brachydanio rerio in behavior analysis instrument record 60min, changed by light dark period, dark 10min, illumination 10min, 60min is divided into three light dark periods, then carries out statistical analysis to the movement velocity (dyskinesia) of Brachydanio rerio, light and shade period velocity change (respond).
quality control standard
this research is tested in strict accordance with following 4 quality control standards: 1. in all experimental grouies, Brachydanio rerio all can not occur death or abnormal phenotype; 2. Senlie dementia model group and solvent control group compare and have significant difference (p<0.05); 3. blank group and solvent control group no difference of science of statistics (p>0.05); 4. positive controls (donepezil, DPZ) compares with Senlie dementia model group and has significant difference (p<0.05).
result and discussion
2.4.1 quality control
this result of study meets quality control standard: 1. in whole experimentation, Brachydanio rerio death or abnormal phenotype all do not appear in all experimental grouies; 2. Senlie dementia model group and solvent control group compare and have significant difference (p<0.05); 3. all experiment empty matched groups no difference of science of statistics (p>0.05) compared with solvent control group; 4. positive controls (donepezil, DPZ) compares with Senlie dementia model group and has significant difference (p<0.05).
lavandula angustifolia activity extract D of the present invention is to the restitution of Senlie dementia model group Brachydanio rerio dyskinesia
the impact (evaluate dyskinesia, Mean ± SE) of lavandula angustifolia activity extract D of the present invention on Senlie dementia model group Brachydanio rerio movement velocity is shown in Table 4; As can be seen from Table 4, Senlie dementia model group Brachydanio rerio movement velocity significantly declines, the average speed of Senlie dementia model group drops to 2.42mm/s from the 2.89mm/s of solvent control group, compares with solvent control group, has statistical significance (p<0.05); Positive controls Brachydanio rerio movement velocity is significantly gone up, the average speed of positive controls goes back up to 2.96mm/s from the 2.42mm/s of Senlie dementia model group, compare with Senlie dementia model group, have statistical significance (p<0.05), movement velocity recovery rate is 22.4%.50 μ g/mL significantly improve (p<0.05) the movement velocity of Brachydanio rerio with the lavandula angustifolia activity extract D of the present invention of 150 μ g/mL compared with Senlie dementia model group, and movement velocity recovery rate is respectively 23.9% and 22.6%; The dyskinesia of lavandula angustifolia activity extract D of the present invention to Brachydanio rerio of 25 μ g/mL is not significantly improved (p>0.05).
lavandula angustifolia activity extract D of the present invention is on the impact of Senlie dementia model group Brachydanio rerio respond
the impact (evaluation response ability, Mean ± SE) of lavandula angustifolia activity extract D of the present invention on Senlie dementia model group Brachydanio rerio speed difference is shown in Table 5; As can be seen from Table 5, Senlie dementia model group Brachydanio rerio respond declines (light and shade period velocity difference significantly declines).The light and shade speed difference of Senlie dementia model group drops to 1.75 from 2.20 of solvent control group, compares with solvent control group, has statistical significance (p<0.05); Positive controls Brachydanio rerio respond part recovers (light and shade period velocity difference is significantly gone up), the light and shade speed difference of many positive controls goes back up to 2.35 from 1.75 of Senlie dementia model group, compare with Senlie dementia model group and have statistical significance (p<0.05), respond recovery rate is 34.1%; 50 μ g/mL significantly improve (p<0.01) the respond of Brachydanio rerio with the lavandula angustifolia activity extract D of the present invention of 150 μ g/mL compared with Senlie dementia model group, respond recovery rate is respectively 51.9% and 42.3%, and the respond of lavandula angustifolia activity extract D of the present invention to Brachydanio rerio of 25 μ g/mL is not significantly improved (p>0.05).
conclusion
lavandula angustifolia activity extract D of the present invention has therapeutical effect to Senlie dementia model group Brachydanio rerio, can not only improve the dyskinesia of Senlie dementia model group Brachydanio rerio, and significantly can recover Senlie dementia model group Brachydanio rerio respond.During 25 μ g/mL, without therapeutical effect; When concentration is 50 μ g/mL, pharmacodynamics has reached or close to maximum.Lavandula angustifolia activity extract D of the present invention is suitable with DPZ to the therapeutical effect of the dyskinesia of Senlie dementia model group Brachydanio rerio, and is slightly better than DPZ to the improvement of respond.
in sum, lavandula angustifolia activity extract A of the present invention, lavandula angustifolia activity extract B, lavandula angustifolia activity extract C, lavandula angustifolia activity extract D and lavandula angustifolia activity extract E all can the responds of recovery Senlie dementia model group Brachydanio rerio in various degree; Lavandula angustifolia activity extract D of the present invention has therapeutical effect to Senlie dementia model group Brachydanio rerio, can not only improve the dyskinesia of Senlie dementia model group Brachydanio rerio, and significantly can recover Senlie dementia model group Brachydanio rerio respond; When concentration is 50 μ g/mL, lavandula angustifolia activity extract D of the present invention is suitable with DPZ to the therapeutical effect of the dyskinesia of Senlie dementia model group Brachydanio rerio, and is better than DPZ to the improvement of respond.
above technical characteristic constitutes embodiments of the invention, and it has stronger adaptability and implementation result, can increase and decrease non-essential technical characteristic according to actual needs, meet the demand of different situations.
Claims (8)
1. the application of lavandula angustifolia activity extract in preparation treatment medicine for senile dementia.
2. the application of lavandula angustifolia activity extract according to claim 1 in preparation treatment medicine for senile dementia, is characterized in that lavandula angustifolia activity extract is lavandula angustifolia activity extract A or lavandula angustifolia activity extract B or lavandula angustifolia activity extract C or lavandula angustifolia activity extract D or lavandula angustifolia activity extract E.
3. the application of lavandula angustifolia activity extract according to claim 2 in preparation treatment medicine for senile dementia, it is characterized in that lavandula angustifolia activity extract A obtains as follows: the first step, lavender flower grain is pulverized and obtains broken lavender flower grain, the ethanol water of broken lavender flower grain 5 doubly to 25 times quality is added in broken lavender flower grain, reflux, extract, 2 times to 3 times at temperature is 45 DEG C to 100 DEG C, each reflux, extract, 0.5h to 1h, lavandula angustifolia extracting solution is obtained after filtrate being merged after reflux, extract, lavandula angustifolia extracting solution is after concentrated and drying, obtain the lavandula angustifolia crude extract that percent mass water content is less than or equal to 15%, second step, the deionized water mix homogeneously adding lavandula angustifolia crude extract 5 doubly to 10 times quality in lavandula angustifolia crude extract obtains suspension, the petroleum ether of suspension 1 doubly to 3 times volume is added and mix homogeneously in suspension, leave standstill 15min to 30min to extract, extract 2 times to 3 times, after extraction, obtain the first raffinate phase, merge each extraction phase and obtain the first extraction phase, first extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract A that percent mass water content is less than or equal to 15%.
4. the application of lavandula angustifolia activity extract according to claim 3 in preparation treatment medicine for senile dementia, it is characterized in that lavandula angustifolia activity extract B obtains as follows: in the first raffinate phase, add the chloroform of the first raffinate phase 1 doubly to 3 times volume and mix homogeneously, leave standstill 15min to 30min to extract, extract 2 times to 3 times, the second raffinate phase is obtained after extraction, merge each extraction phase and obtain the second extraction phase, second extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract B that percent mass water content is less than or equal to 15%.
5. the application of lavandula angustifolia activity extract according to claim 4 in preparation treatment medicine for senile dementia, it is characterized in that lavandula angustifolia activity extract C obtains as follows: in the second raffinate phase, add the ethyl acetate of the second raffinate phase 1 doubly to 3 times volume and mix homogeneously, leave standstill 15min to 60min to extract, extract 2 times to 3 times, the 3rd raffinate phase is obtained after extraction, merge each extraction phase and obtain the 3rd extraction phase, 3rd extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract C that percent mass water content is less than or equal to 15%.
6. the application of lavandula angustifolia activity extract according to claim 5 in preparation treatment medicine for senile dementia, it is characterized in that lavandula angustifolia activity extract D obtains as follows: in the 3rd raffinate phase, add the n-butyl alcohol of the 3rd raffinate phase 1 doubly to 3 times volume and mix homogeneously, leave standstill 15min to 60min to extract, extract 2 times to 3 times, the 4th raffinate phase is obtained after extraction, merge each extraction phase and obtain the 4th extraction phase, 4th extraction phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract D that percent mass water content is less than or equal to 15%.
7. the application of lavandula angustifolia activity extract according to claim 6 in preparation treatment medicine for senile dementia, it is characterized in that lavandula angustifolia activity extract E obtains as follows: the 4th raffinate phase is through concentrating and after drying, obtaining the lavandula angustifolia activity extract E that percent mass water content is less than or equal to 15%.
8. the application of the lavandula angustifolia activity extract according to claim 3 or 4 or 5 or 6 or 7 in preparation treatment medicine for senile dementia, is characterized in that in the first step, ethanol water to be percent by volume be 10% to 90% ethanol water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510528733.7A CN105326900A (en) | 2015-08-25 | 2015-08-25 | Application of lavender active extract in preparing drug for treating senile dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510528733.7A CN105326900A (en) | 2015-08-25 | 2015-08-25 | Application of lavender active extract in preparing drug for treating senile dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105326900A true CN105326900A (en) | 2016-02-17 |
Family
ID=55277806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510528733.7A Pending CN105326900A (en) | 2015-08-25 | 2015-08-25 | Application of lavender active extract in preparing drug for treating senile dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105326900A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112062870A (en) * | 2020-09-26 | 2020-12-11 | 张超科 | Polysaccharide with whitening and moisturizing activities, whitening and moisturizing cream containing polysaccharide and preparation method of whitening and moisturizing cream |
| CN112243898A (en) * | 2020-11-09 | 2021-01-22 | 井冈山大学 | Zebra fish cerebral arterial thrombosis model, construction method and application |
| CN115869226A (en) * | 2022-11-30 | 2023-03-31 | 西安迦柏丽生物科技有限公司 | Hyaluronic acid-containing composition and application thereof in preparation of product with repairing effect |
-
2015
- 2015-08-25 CN CN201510528733.7A patent/CN105326900A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| MASOUD SOHEILI KASHANI ET AL: "Aqueous extract of lavender (Lavandula angustifolia) improves the spatial performance of a rat model of Alzheimer’s disease", 《NEUROSCI BULL》 * |
| 王雪飞等: "复方薰衣草糖浆对半乳糖致老年痴呆模型小鼠的保护作用", 《中药药理与临床》 * |
| 罗碧等: "薰衣草花提取物对酪氨酸酶的抑制作用研究", 《日用化学工业》 * |
| 蒲韵竹: "斑马鱼阿尔茨海默病动物模型的建立", 《西南大学硕士学位论文》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112062870A (en) * | 2020-09-26 | 2020-12-11 | 张超科 | Polysaccharide with whitening and moisturizing activities, whitening and moisturizing cream containing polysaccharide and preparation method of whitening and moisturizing cream |
| CN112062870B (en) * | 2020-09-26 | 2022-04-12 | 菲诗倾城(广州)生物科技有限公司 | Polysaccharide with whitening and moisturizing activities, whitening and moisturizing cream containing polysaccharide and preparation method of whitening and moisturizing cream |
| CN112243898A (en) * | 2020-11-09 | 2021-01-22 | 井冈山大学 | Zebra fish cerebral arterial thrombosis model, construction method and application |
| CN115869226A (en) * | 2022-11-30 | 2023-03-31 | 西安迦柏丽生物科技有限公司 | Hyaluronic acid-containing composition and application thereof in preparation of product with repairing effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102548571B (en) | Compositions and methods for prevention and treatment of brain diseases and conditions | |
| CN112245596B (en) | Method for screening drug effect substances based on zebra fish inflammatory bowel disease model | |
| WO2012040938A1 (en) | Use of fucoxanthin in the preparation of product having neuroprotective effect associated with neurodegenerative disorder and improving memory | |
| Xiong et al. | The microplastics exposure induce the kidney injury in mice revealed by RNA-seq | |
| CN105326900A (en) | Application of lavender active extract in preparing drug for treating senile dementia | |
| Liu et al. | Strain-dependent differential behavioral responses of zebrafish larvae to acute MK-801 treatment | |
| JP6696972B2 (en) | Use of ginsenoside M1 to treat lupus nephritis | |
| Yang et al. | Baicalin rescues cognitive dysfunction, mitigates neurodegeneration, and exerts anti-epileptic effects through activating TLR4/MYD88/caspase-3 pathway in rats | |
| CN101530410B (en) | Application of oligomeric proantho cyanidins in preparing products resisting vascular dementia | |
| CN114452275A (en) | Application of vitamin B5 in preparation of medicine or preparation for preventing and/or treating Th17 cell related diseases | |
| Gao et al. | Various fractions of alcoholic extracts from dendrobium nobile functionalized antioxidation and antiaging in D-Galactose-induced aging mice | |
| CN102784160B (en) | Application of forsythin to preparation of medicine for improving cognitive function and treating Alzheimer's diseases | |
| Anguchamy et al. | Enhancing the neuroprotective effect of squid outer skin astaxanthin against rotenone-induced neurotoxicity in in-vitro model for Parkinson's disease | |
| CN102813646B (en) | Application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis, homomangiferin pharmaceutical compositions and homomangiferin preparations | |
| CN115770251A (en) | Application of polysaccharide in preparing medicine for preventing and/or treating ulcerative colitis | |
| CN102379914A (en) | Pharmaceutical composition for treating Alzheimer disease (AD), and preparation method and application thereof | |
| CN102018747B (en) | Application of red stilbene and red stilbene polysaccharide in preparing medicament for improvement of learning memory and treatment of Alzheimer disease | |
| CN114767730A (en) | New application of radix Puerariae extract in preventing and treating intestinal flora disturbance | |
| CN104055731B (en) | A kind of coccidiostat fluoroadenine solution and preparation method thereof | |
| CN104083345A (en) | Application of lycopene in preparation of medicine for prevention and treatment senile dementia | |
| CN105412195A (en) | Chrysanthemum stem and leaf refined polysaccharide extract with effect of treating acute colitis and application thereof | |
| CN112451559A (en) | Use of flos Puerariae Lobatae extract in preventing and treating oxidative damage | |
| CN112546032A (en) | New application of phloretin | |
| CN104130232B (en) | The method of purification of a kind of EGCG and the EGCG of acquisition and pharmaceutical composition | |
| CN104171797A (en) | Application of ginseng and polygonum multiflorum compound polysaccharide in preparation of health foods with anti-aging effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160217 |